BUY IPCA Laboratories Limited — Motilal Oswal
byMotilal OswalHorizon: NA (inferred 1 year)14 Aug 2026via Institutional / Brokerage Research
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Long-term trend bullish — 200-day average rising over the past quarter
Technicals · trend·23 Oct · yesterday
3 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days
Advisor consensus · adjacent horizon·23 Oct · yesterday
1 other SEBI-registered advisor has an active long-term BUY call on this stock, issued in the last 14 days
Advisor consensus · same horizon·23 Oct · yesterday
Ipca Laboratories stock reports stronger Q1 growth as guidance rises
NewsGoogle News·7 Oct · 2w ago
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on IPCA Laboratories
- BUY — Vikas Sethi, Sethi Finmart23 Oct 2026 · ~1 year · target ₹2,250 · Active
- BUY — Kunal Saraogi23 Oct 2026 · ~3 months · target ₹2,350 · Active
- BUY — Manas Jaiswal22 Oct 2026 · ~2 weeks · target ₹2,000 · Active
- BUY — Vikas Sethi, Sethi Finmart8 Oct 2026 · ~1 year · target ₹2,300 · SL hit
- BUY — Sudeep Shah, SBICAP Securities5 Oct 2026 · ~3 months · target ₹2,040 · SL hit
More from Motilal Oswal
- BUY Colgate Palmolive (India)22 Oct 2026 · ~1 year · target ₹2,000 · Active
- BUY Sapphire Foods India22 Oct 2026 · ~1 year · target ₹245 · Active
- BUY CIE Automotive India22 Oct 2026 · ~1 year · target ₹440 · Active
- BUY CREDITACCESS GRAMEEN22 Oct 2026 · ~1 year · target ₹1,450 · Active
- BUY KEI Industries22 Oct 2026 · ~1 year · target ₹5,180 · Active

